QTc Intervals in Former Preterm/Extreme Low Birth Weight Infants: a Pooled Study Proposal

Sponsor
Universitaire Ziekenhuizen Leuven (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05243537
Collaborator
St. Justine's Hospital (Other)
250
2
4
125
31.2

Study Details

Study Description

Brief Summary

Pooling effort to collect previously reported data on QTc time in former preterm neonates, and compare these data to controls. At present and based on a recently conducted systematic search, there are conflicting data on the potential QT interval prolongation (all Bazett) in former extreme low birth weight (ELBW, <1000 g) infants or preterms.

Consequently, if investigators truly want to assess the presence or absence of either a difference or a prolongation of QTc intervals in this specific population, pooling of published data is likely the most effective approach (potential number of cases = 24 + 49 + 93 = 166; potential number of controls in the same studies = 24 + 53 + 87 = 164), preferably based on individual data.

Although the sample is to a large extent pragmatic (as available), the investigators hereby aim to target the 5 ms QTc prolongation applied by the authorities (FDA, EMA) in paired healthy adult volunteer studies as 'golden' standard as primary outcome variable [EMA guideline, FDA guidance].

Condition or Disease Intervention/Treatment Phase
  • Other: ECG (diagnostic)

Detailed Description

Preterm birth and gestational age at birth are associated with an increased risk for cardiovascular morbidity and mortality. In a large population-based cohort study with an incidence of preterm birth of 5.4 %, the adjusted hazard ratio of all-cause mortality in former preterms (23-33 weeks) was 1.44 in young adulthood (<50 years), most pronounced for cardiovascular mortality (1.89), diabetes (1.98) and chronic lung disease (2.28). Interestingly, the increased death risk was found across gestational age up to the ideal term age (39-41 weeks), but most prominent for the most immature group.

Besides better understanding of the underlying mechanisms associated with the 'Barker' and 'Brenner' cardiovascular risk hypotheses, there is an obvious need to further explore biomarkers to detect potential higher risk besides the gestational age or birth weight to translate this knowledge to clinical practice or secondary prevention strategies.

In a recent meta-analysis on changes in the preterm heart from birth to young adulthood, it was concluded that former preterms have morphological and functional cardiac impairments, proportionally to the degree of prematurity. In contrast to the echocardiographic differences in left and right ventricular systolic functions in former preterm when compared to term controls, observations on electrocardiographic (ECG) findings are less conclusive. Whether preterm birth is associated with conduction or repolarization abnormalities later in life is less well explored.

At present and based on a recently conducted systematic search, there are conflicting data on the potential QT interval prolongation (all Bazett) in former extreme low birth weight (ELBW, <1000 g) infants (data reported chronological).

Bassareo et al. reported that corrected QT (QTc) intervals and QT dispersion (QTd) were significantly prolonged in 24 former ELBW cases compared to 24 term controls (mean, ± SD: 417, 23.6 versus 369, 19.5 ms, and 30.4, 14.1 versus 24.6, 8.2 ms, respectively) (age at assessment = 23.2, SD 3.3 years).

Gervais et al. could subsequently not confirm these findings in 49 preterm cases (<30 weeks) when compared to 53 term born controls. At rest, mean QTc were 408, ± 34 and 409, ±SD 31 ms respectively (age at assessment = 18-33 years). Post-hoc power calculations showed that this study had 80% power to detect a difference of at least 18 ms in QTc between the two groups.

Finally, based on the PREMATCH study (ClinicalTrials.gov NCT02147457, S 56577), data on QTc observations are also available. QTc and QTd were similar between 93 ELBW cases and 87 controls [409 (range 360-465) versus 409 (337-460); 40 (0-100) versus 39 (0-110)] ms. When expressed by mean and SD, 409 (23) ms in the full dataset, 409 (SD 22) in former ELBW cases, 409 (SD 24) in controls [Salaets et al, Pediatr Res 2022]. Age, height, weight or body mass index were not associated with the QTc interval, while female sex (median difference 11.4 ms) and lower potassium (r=-0.26) were associated with longer QTc interval. We could not observe any significant association between QTc interval and perinatal characteristics (age at assessment 8-14 years). Post hoc analysis showed that our study had a power of 90 % to detect a difference of 11,45 ms between both groups.

Consequently, if researchers truly want to assess the presence or absence of either a difference or a prolongation of QTc intervals in this specific population, pooling of published data is likely the most effective approach (potential number of cases = 24 + 49 + 93 = 166; potential number of controls in the same studies = 24 + 53 + 87 = 164), preferably based on individual data. Although the sample is to a large extent pragmatic (as available), the investigators hereby aim to target the 5 ms QTc prolongation applied by the authorities (FDA, EMA) in paired healthy adult volunteer studies as 'golden' standard as primary outcome variable [EMA guideline, FDA guidance]. In all 3 cohorts, perinatal characteristics (like gestational age, weight, or pre- or postnatal steroids) were explored on their potential impact on the QTc interval, but all cohorts were underpowered to draw firm conclusions, so that these analyses will be included as secondary analyses.

Descriptive statistics will be used to report on the pooled dataset, and will be reported by mean and standard deviation, or median and range, pending normal distribution characteristics or incidence (%), (cases and controls, or cases only, respectively).

Statistical analysis will be used (two-tailed or one-tailed) to explore the relation of the data to the underlying population(s), like Rank correlation, Mann Whitney U or t-test (cases to controls, and within cases respectively). Based on the individual cohorts published, it is reasonable to anticipate normal distribution.

Power exploration using Mann-Whitney-U tests at alfa = 0,05 In order to find a significant two-tailed difference of 5ms, with a power of 90 % and extrapolating from the data distribution of the Leuven cohort, it was estimated that 467 subjects are required in both case and control groups. Decreasing the power to 80 % still requires 349 subjects in each group. In order to find a significant one-tailed difference of 5ms, with a power of 90 % and using the data distribution of the Leuven cohort, it was estimated that 381 subjects are required in both case and control groups.

Decreasing the power to 80 % still requires 275 subjects in each group (when using the FDA and EMA criteria to exclude an increase of 5 ms in former preterm cases).

In order to find a significant two-tailed difference of 10ms, with a power of 90 % and extrapolating from the data distribution of the Leuven cohort, it was estimate 118 subjects are required in both case and control groups. Decreasing the power to 80 % requires 88 subjects in each group.

In order to find a significant one-tailed difference of 10ms, with a power of 90 % and using the data distribution of the Leuven cohort, it was estimated that 96 subjects are required in both case and control groups. Decreasing the power to 80 % requires 70 subjects in each group. Inversely, having 166 and 164 subjects in each group and extrapolating the Leuven distribution data, this will have 90 % power to significantly discriminate a difference of 8.43ms (two-tailed) or 7.60ms (one-tailed), or 80 % power to significantly discriminate a difference of 7.28ms (two-tailed) or 6.46ms (one-tailed). Due to differences in data distribution between the cohorts: the actual discriminative power will probably be lower (the Leuven cohort -used for this estimation- has the narrowest standard deviation, and the Italian cohort has a different mean).

The investigators intend to conduct a post hoc power analysis with a difference (hypothesis:

the mean QTc is not >5 ms higher in former preterm neonates compared to controls).

Study Design

Study Type:
Observational
Anticipated Enrollment :
250 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
QTc Intervals in Former Preterm/Extreme Low Birth Weight Infants: a Pooled Study Proposal
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
QTc time interval in former preterm neonates, or term born healthy controls

former preterms and healthy term controls are defined as described in the cohort as previously published (Salaets et al, Pediatr Res 2021; Gervais et al, Pediatr Res 2020; Bassareo et al, J Matern Fetal Neonatal Med 2011). This includes both the perinatal characteristics as well as the characteristics collected at assessment (pediatric age or young adulthood) In all cases, an ECG was collected at rest, and these individual values (preterm or healthy term controls will be pooled.

Other: ECG (diagnostic)
ECG collection (once, at rest), in both cases and controls

Outcome Measures

Primary Outcome Measures

  1. QTc time interval [1 year]

    QTc time interval (in msec) in former preterms or healthy term controls

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 25 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • included as 'case' in one of the cohorts retrieved by a systematic search on QTc values in former preterm neonates compared to healthy controls, or.

  • included a 'control' in one of the cohorts retrieved by a systematic search on QTc values in former preterm neonates compared to healthy controls.

Exclusion Criteria:
  • not included as 'case' in any of the cohorts retrieved by systematic search on QTc values in former preterm neonates compared to healthy controls

  • not included as 'control' in any of the cohorts retrieved by systematic search on QTc values in former preterm neonates compared to healthy controls

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Leuven Leuven Belgium 3000
2 Centre Hospitalier Universitair Sainte-Justine Montréal Quebec Canada

Sponsors and Collaborators

  • Universitaire Ziekenhuizen Leuven
  • St. Justine's Hospital

Investigators

  • Principal Investigator: karel allegaert, MD, PhD, UZ Leuven

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT05243537
Other Study ID Numbers:
  • S66020
First Posted:
Feb 17, 2022
Last Update Posted:
Jul 8, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Universitaire Ziekenhuizen Leuven
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 8, 2022